Articles tagged with Hematology
The Blood editors have selected the top 10 manuscripts of 2018, showcasing notable advances in various hematological disorders. These studies highlight promising treatments for B-cell precursor acute lymphoblastic leukemia and classical Hodgkin lymphoma, as well as novel therapeutic strategies for immune thrombocytopenia.
Dr. Nazha presents results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes (MDS), predicting patient mortality and transformation risk with high accuracy.
The new guidelines from the European Hematology Association and European LeukemiaNet provide standardized approaches to clinical management of Chronic Myelomonocytic Leukemia (CMML). The recommendations are based on expert consensus and include steps to improve evidence supporting clinical guidelines.
The American Society of Hematology has released new clinical practice guidelines for venous thromboembolism, covering evidence-based recommendations for prevention, diagnosis, and treatment. The guidelines aim to improve care for patients with blood clots, addressing current uncertainties and variations in clinical practice.
A phase III trial shows duvelisib significantly extends progression-free survival, offering a new treatment option for patients with relapsed or treatment-resistant CLL and SLL. The therapy also works well in sub-group analyses for hardest-to-treat cases with limited options.
Patients taking JAK inhibitors for myelofibrosis are at increased risk of developing aggressive B-cell lymphomas. Screening for a preexisting B-cell clone before treatment may help prevent this side effect.
A new report calls for better evaluation of side effects from modern blood cancer treatments, which have dramatically improved survival rates. The Commission proposes new approaches to reporting adverse events, including capturing chronic and cumulative effects.
A new study suggests that adolescents and young adults with acute leukemia have a survival advantage when receiving treatment at pediatric cancer centers versus adult centers, particularly those affiliated with the National Cancer Institute. This is due to the more experienced care teams in these settings.
The Harry T. Mangurian Jr. Foundation has donated $20 million to Mayo Clinic to name a new medical building for cancer and neurologic care. The building will double the size of existing departments and support increased staff and research.
Dr. Benjamin Ebert has made significant contributions to understanding the genomic landscape of adult myelodysplastic syndromes (MDS) and its impact on both hematologic malignancies and cardiovascular disease. He is also known for his work on precision medicine and his innovative approaches to treating diseases.
Researchers developed a genetic model that predicts outcomes in primary myelofibrosis patients under 70 using gene mutations and clinical variables. The model improves on previous predictive models, which only used clinical variables.
A study of people with chronic lymphocytic leukemia (CLL) found that effectiveness and adverse events are top concerns when choosing treatment. Patients are willing to trade off some drug efficacy for reduced risk of serious side effects, but out-of-pocket costs can significantly influence their choices.
Dr. Betty S. Pace will receive the ASH Leadership in Promoting Diversity Award for her commitment to diversity and inclusion in hematology. She has trained over 80 underrepresented minority individuals, including 45% of those she has personally mentored.
Orly Leiva, a fourth-year medical student at Boston University School of Medicine, has been named to the 2017 Minority Medical Student Award Program. The program supports underrepresented minority students pursuing hematology research projects with $7,000 funding and mentorship.
Researchers at the American Society of Hematology report on the effectiveness of enasidenib in treating a rare form of leukemia. Enasidenib demonstrates significant benefits as a targeted treatment for this aggressive disease, offering new hope for patients with limited options.
The American Society of Hematology has awarded $150,000 in Bridge Grants to five researchers to sustain their hematologic research proposals. The grants will help preserve programs at institutions across the US and encourage the retention of promising researchers in uncertain NIH funding environments.
Pacritinib significantly reduces spleen size among people with very low levels of platelets, while a twice-daily dose improves symptoms. The study also showed that pacritinib is effective in treating patients who have previously been treated with ruxolitinib.
Researchers from UH Rainbow presented data on improving clinical outcomes for pediatric hematologic disorders, including findings on acquired aplastic anemia treatment algorithms and red blood cell transfusions in critically ill children. The studies aimed to improve long-term outcomes and transplant options for these rare diseases.
Researchers from Mount Sinai Health System presented various studies on multiple myeloma and other hematological disorders at the American Society of Hematology's Annual Meeting. The studies focused on treatment protocols, biomarkers, and gene expression in these diseases.
The American Society of Hematology launched Blood Advances, an open-access online journal, to fill a niche in hematologic research. The journal features multimedia content, rapid publication, and interactive discussion tools.
The American Society of Hematology has partnered with several organizations to create a specialized curriculum for acute myeloid leukemia (AML) care. The program aims to address knowledge gaps in the entire multidisciplinary team involved in AML management, including accurate diagnosis, risk stratification, and treatment options.
The American Society of Hematology (ASH) has established a $3 million annual Bridge Grant program to support blood disease research. This initiative aims to ensure that promising researchers in hematology continue their work despite limited NIH funding.
Generic drugs are increasingly inaccessible due to pharmaceutical companies' strategies to delay market entry. These tactics include pay-for-delay deals, authorized generics, and product hopping, which can lead to higher prices for patients.
A majority of hematologic oncologists report that end-of-life discussions happen too late, with most discussions occurring when death was clearly imminent. The delay may be attributed to the curative potential of many advanced hematologic cancers, leading to a lack of clear distinction between curative and palliative care phases.
A new antibody called ACE910 has shown promising results in reducing the need for frequent injections in patients with severe hemophilia A. The study found that ACE910 is safe and effective in preventing excessive bleeding, even in patients who develop antibodies to existing treatments.
A study found that sirolimus successfully resolved autoimmune conditions in children with ALPS without adverse side effects. The treatment improved blood cell counts and quality of life for patients, making it a potential early therapy option.
A study found that patients with persistent Coxiella burnetii infections, which cause Q fever, are at a higher risk of developing non-Hodgkin lymphoma. The researchers discovered that these patients often have overproduction of interleukin-10, allowing the cancer cells to evade immune detection.
Patients with light-chain (AL) amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival. Nearly one-third of patients achieved up to 20-year survival after treatment.
A Phase 2 open-label study found that brentuximab vedotin achieved a high response rate, including complete remissions, in older Hodgkin lymphoma patients unfit for chemotherapy. The treatment was generally well-tolerated, with peripheral sensory neuropathy being the most common adverse event.
A McMaster University hematologist has identified various limb loss syndromes, including symmetric peripheral gangrene and venous limb gangrene, which can be caused by septic shock, cancer, and blood clotting disorders. The treatment for these conditions involves the use of blood thinners and replacement of protective factors.
The American Society of Hematology proposes a new role for hematologists in a rapidly changing US healthcare system. The 'systems-based' clinical hematologist model offers a sustainable approach to recruit and retain talent in the field.
A new study published in The Lancet Haematology found that PET-CT is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma. The findings suggest that PET-CT should be used routinely in clinical practice to improve patient outcomes.
An experimental drug has demonstrated potential as a first treatment for anemia of inflammation, regulating blood's iron supply and maintaining its transport. The treatment, lexaptepid pegol, inactivates hepcidin hormone production, improving iron levels without interfering with the immune response.
Geraldine P. Schechter, MD, receives the 2014 Henry M. Stratton Medal for Clinical Science for her pioneering work on chronic lymphoid malignancies and autoimmune hematologic disorders. Timothy Springer, PhD, wins the award for Basic Science for his groundbreaking research on hemostasis, inflammation, and immunology.
Drs. DeBaun and Hebbel will present their lecture on sickle cell disease, highlighting improved understanding but continued challenges. Their research focuses on cerebrovascular injury and asthma, with implications for treatment and care.
The American Society of Hematology awards Mentor Awards to Drs. Grover C. Bagby Jr., MD, and John F. DiPersio, MD, PhD, for their dedication to mentoring early-career hematologists. Both mentors have had a significant impact on the careers of numerous mentees, advancing research and patient care in hematology.
Dr. Tomas Ganz is recognized for his pioneering work on iron homeostasis and the discovery of the hormone hepcidin, which plays a crucial role in regulating iron metabolism. His research has significant implications for understanding and treating iron deficiency anemia and inflammation.
A comprehensive 'roadmap' of blood cells has been presented by researchers, pinpointing the location of key genetic regulators that determine cell development and function. This robust genetic catalog will enable hematologists to trace the development of blood cells and identify potential triggers for malignancies.
The American Society of Hematology has released a list of common hematology tests, treatments, and procedures that are not always necessary. The list highlights five tests or procedures to question, including limiting surveillance CT scans in asymptomatic patients following curative-intent treatment for aggressive lymphoma.
A new report illustrates a surprisingly large global burden of anemia, characterized by low hemoglobin levels and impaired oxygen delivery to the body. Despite decreasing prevalence between 1990 and 2010, anemia remains a significant health issue, particularly among young children and women in low- and middle-income regions.
Researchers developed a drug regimen that eradicated CRE colonization in 44% of patients, significantly reducing mortality rates. The treatment was found to be safe and effective for eliminating the carrier state, which can reduce patient-to-patient transmission.
A study by the American Society of Hematology found that bone marrow transplant is linked to diminished sexual health in both men and women. Chronic graft-versus-host disease and total body irradiation are particularly damaging, with men experiencing a decline in libido and dysfunction.
Nancy Andrews, MD, PhD, was recognized for her work on iron homeostasis and erythropoiesis, while Elaine Jaffe, MD, received the award for her clinical/traslational research on lymphoma. Both scientists have made significant contributions to their respective fields.
Kenneth Kaushansky and David J. Kuter are honored with the 2013 Ernest Beutler Lecture for their significant advances in thrombopoietin, a growth factor regulating platelet production. Drs. Kaushansky and Kuter will present their lecture on December 9 at the 55th ASH Annual Meeting.
Dr. Andrew S. Weyrich receives the 2013 William Dameshek Prize for his seminal work on the cellular and molecular causes of blood clots, revolutionizing our understanding of platelet function. His research has far-reaching implications in hematology and beyond.
Katherine A. High, MD, receives the 2013 E. Donnall Thomas Lecture and Prize for her pioneering research on gene therapy for hemophilia and inherited retinal degenerative diseases. Her work has led to sustained clinical improvements using adeno-associated virus vectors.
Researchers used MFC and RQ-PCR to monitor minimal residual disease in patients with Ph+ ALL, finding that a negative reading was associated with prolonged survival. The study suggests that these technologies may be effective in predicting patient outcomes and guiding treatment decisions.
A new liposomal formulation of anthracycline-based chemotherapy has shown promising results in treating pediatric leukemia patients, with high survival rates and minimal heart toxicity. The treatment regimen was found to be effective at higher-than-standard doses without causing added cardiotoxicity.
Researchers propose a novel risk stratification model for bladder cancer patients treated with radical cystectomy, utilizing clinico-pathological and pre-operative hematological factors. The study found that low hemoglobin and high C-reacted protein levels are independent prognostic indicators for disease-specific survival.
An ASH international clinical network collaboration improved APL survival rates by replicating a high cure rate of 85% in patients in Central and South America. The standard-of-care protocol, including oral ATRA and daunorubicin-based chemotherapy, showed promising results with low cumulative incidence of relapse.
Researchers have identified a new approach to treating lymphoma by combining a toll-like receptor agonist with radiation, resulting in durable anti-tumor immune responses. Additionally, scientists have developed model-based decision rules to predict the safety of therapy discontinuation for patients with chronic myeloid leukemia.
A new study reveals cultural and social factors that hinder minority participation in stem cell donation, leading to lower patient success rates. Minority donors are more likely to opt-out due to concerns about health complications and mistrust of the medical system.
A survey of American researchers at the ASH annual meeting found that 63% relied on NIH funding for their studies. This reliance is seen across both U.S. and international respondents, with 75% expressing extreme concern about potential budget cuts.
Researchers present promising results from a Phase II study on quizartinib, a targeted therapy that may turn treatment-resistant leukemia into manageable conditions. The study shows great potential in turning fatal disease subtypes into chronic conditions with regular treatment.
Researchers found that ibrutinib effectively treats CLL with high response rates and durable remissions, particularly in elderly patients. The study also showed manageable toxicities, with only non-severe side effects observed.
Researchers examined current treatment standards for patients with clotting disorders, aiming to reduce toxicities and relapse rates. Maintaining hematocrit levels below 45% was associated with a lower risk of thrombosis compared to a more liberal approach.
Dr. Margaret A. Goodell is awarded the 2012 William Dameshek Prize for her groundbreaking work on hematopoietic stem cells and their role in regulating the immune response.
Dr. James George is recognized for his pioneering work on platelet glycoproteins, diagnosis and clinical management of idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP). He has also made significant contributions to education, research, and practice through various initiatives.
Researchers found that the CyBorD/CVD regimen can lead to complete hematologic response and may make AL amyloidosis patients eligible for stem cell transplants. This effective multiple myeloma treatment is already widely used, offering a potential therapy for those with few treatment options.
For the first time, researchers have successfully injected cultured red blood cells (cRBCs) created from human hematopoietic stem cells (HSCs) into a human donor. The cRBCs were capable of progressing through the full maturation process and demonstrated survival rates comparable to conventional native red blood cells.